Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.560
+0.050 (3.31%)
Jan 29, 2026, 3:36 PM EST - Market open
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $2.82M in the twelve months ending September 30, 2025, down -82.53% year-over-year. In the year 2024, Pyxis Oncology had annual revenue of $16.15M.
Revenue (ttm)
$2.82M
Revenue Growth
-82.53%
P/S Ratio
33.04
Revenue / Employee
$64,091
Employees
44
Market Cap
97.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 58.42M |
| MindWalk Holdings | 19.02M |
| Korro Bio | 7.37M |
| Coya Therapeutics | 3.99M |
| Cibus | 3.79M |
| Precision BioSciences | 698.00K |
| Inovio Pharmaceuticals | 182.34K |
PYXS News
- 5 weeks ago - Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
- 6 weeks ago - Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript - Seeking Alpha
- 6 weeks ago - Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 3 months ago - Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings - GlobeNewsWire
- 4 months ago - Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - GlobeNewsWire
- 4 months ago - Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire